Progression-free survival curves and overall survival curves. Compared with the historical cisplatin group, the carboplatin group showed no statistically significant difference in terms of recurrence (hazard ratio [HR], 1.21; 95% confidence interval [CI], 0.52–2.81; p = .66) and survival (HR, 1.80; 95% CI, 0.49–6.54; p = .38).
Abbreviations: CarboRT, carboplatin-based chemoradiotherapy; CisRT, cisplatin-based chemoradiotherapy.